These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6145309)

  • 1. Systemic sclerosis: successful treatment of ulcerations, pain, Raynaud's phenomenon, calcinosis, and dysphagia by transcutaneous nerve stimulation. A case report.
    Kaada B
    Acupunct Electrother Res; 1984; 9(1):31-44. PubMed ID: 6145309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of esophageal dysmotility and Raynaud's phenomenon in systemic sclerosis and achalasia by transcutaneous nerve stimulation. Increase in plasma VIP concentration.
    Kaada B
    Scand J Gastroenterol; 1987 Nov; 22(9):1137-46. PubMed ID: 3501154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spinal cord stimulation for the treatment of progressive systemic sclerosis and Raynaud's syndrome.
    Francaviglia N; Silvestro C; Maiello M; Bragazzi R; Bernucci C
    Br J Neurosurg; 1994; 8(5):567-71. PubMed ID: 7857537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spinal cord stimulation utilization to treat the microcirculatory vascular insufficiency and ulcers associated with scleroderma: a case report and review of the literature.
    Provenzano DA; Nicholson L; Jarzabek G; Lutton E; Catalane DB; Mackin E
    Pain Med; 2011 Sep; 12(9):1331-5. PubMed ID: 21914119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic sclerosis: Current concepts of skin and systemic manifestations.
    Pearson DR; Werth VP; Pappas-Taffer L
    Clin Dermatol; 2018; 36(4):459-474. PubMed ID: 30047430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic management of acral manifestations of systemic sclerosis].
    Meyer MF; Daigeler A; Lehnhardt M; Steinau HU; Klein HH
    Med Klin (Munich); 2007 Mar; 102(3):209-18. PubMed ID: 17345017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcutaneous electrical nerve stimulation (TENS) in Raynaud's phenomenon.
    Mulder P; Dompeling EC; van Slochteren-van der Boor JC; Kuipers WD; Smit AJ
    Angiology; 1991 May; 42(5):414-7. PubMed ID: 2035894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sclerodermic acrosyndromes].
    Carpentier PH
    Rev Prat; 2002 Nov; 52(17):1891-5. PubMed ID: 12532865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Raynaud phenomenon and ischemic ulcers associated to systemic sclerosis with hyperbaric oxygen.
    Ahijón-Lana M; Baragaño-Ordóñez E; Veiga-Cabello R; de la Cruz-Tapidor C; Carreira PE
    Reumatol Clin (Engl Ed); 2022 Apr; 18(4):246-248. PubMed ID: 34953734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spinal cord stimulation for the treatment of pain and toe ulceration associated with systemic sclerosis: a case report.
    Ito H; Tanei T; Sugawara K; Sando Y; Hori N
    Fukushima J Med Sci; 2022 Apr; 68(1):37-41. PubMed ID: 35228457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of biofeedback training in treatment of Raynaud's disease and phenomenon.
    Yocum DE; Hodes R; Sundstrom WR; Cleeland CS
    J Rheumatol; 1985 Feb; 12(1):90-3. PubMed ID: 3981523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and objective data on spinal cord stimulation for the treatment of severe Raynaud's phenomenon.
    Neuhauser B; Perkmann R; Klingler PJ; Giacomuzzi S; Kofler A; Fraedrich G
    Am Surg; 2001 Nov; 67(11):1096-7. PubMed ID: 11730228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 25. Ischemic pain in the extremities and Raynaud's phenomenon.
    Devulder J; van Suijlekom H; van Dongen R; Diwan S; Mekhail N; van Kleef M; Huygen F
    Pain Pract; 2011; 11(5):483-91. PubMed ID: 21435165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease.
    Gerbracht DD; Steen VD; Ziegler GL; Medsger TA; Rodnan GP
    Arthritis Rheum; 1985 Jan; 28(1):87-92. PubMed ID: 3871330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of acral circulation in a patient with systemic sclerosis with stellate blocks.
    Klyscz T; Jünger M; Meyer H; Rassner G
    Vasa; 1998 Feb; 27(1):39-42. PubMed ID: 9540432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome].
    Hostein J; Bost R; Carpentier P; Franco A; Fournet J
    Gastroenterol Clin Biol; 1985 Feb; 9(2):130-5. PubMed ID: 3979734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of systemic sclerosis.
    Pope JE
    Rheum Dis Clin North Am; 1996 Nov; 22(4):893-907. PubMed ID: 8923602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.